<DOC>
	<DOCNO>NCT02709798</DOCNO>
	<brief_summary>The purpose study evaluate whether perioperative use Shenfu Injection could reduce myocardial injury ( enzymatic infarct size infarct volume accord cardiac magnetic resonance imaging ) patient STEMI primary PCI</brief_summary>
	<brief_title>ShenFu Injection Myocardial Protection Patients With Acute ST Segment Elevation Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Reperfusion Injury</mesh_term>
	<criteria>1 . Age ≥18 &lt; 75 year ; 2 . Firsttime acute anterior STEMI ; 3 . The time onset ischemic symptom time initial PCI balloon inflation ≤6 hour ; 4 . &gt; 0.1 mV ST segment elevation least two contiguous precordial lead accord electrocardiogram ; 5 . Scheduled primary PCI ; 6 . The presence leave anterior descend branch ( LAD ) occlusion proximal middle segment prePCI TIMI flow 0 1 accord baseline coronary angiogram ; 7 . Written informed consent . 1 . Hypertrophic cardiomyopathy , aortic valve stenosis and/or regurgitation , pericarditis , myocarditis ; 2 . Cardiogenic shock , severe ventricular arrhythmia , serious heart failure ( Killip class III ) mechanical complication ; 3 . Patients cardiopulmonary resuscitation ( CPR ) ( include cardioversion ) ; 4 . Patients already receive thrombolytic therapy ; 5 . Prior myocardial infarction coronary artery bypass surgery ; 6 . Known serious hepatic , renal , blood , respiratory , neuropsychiatric disease ; 7 . Malignant tumor , lymphoma , HIVpositive , hepatitis ; 8 . Uncontrolled hypertension ( systolic BP &gt; 160 mm Hg diastolic BP &gt; 100 mmHg least two consecutive reading ) ; 9 . Patients active bleeding , major surgery trauma within 3 month cerebrovascular accident within 6 month ; 10 . History anemia ( hemoglobin &lt; 90g/L ) thrombocytopenia ( thrombocyte &lt; 90×109/L ) ; 11 . Multivessel disease nonculprit vessel intervention ; 12 . Breastfeeding , pregnant , potentially fertile woman ; 13 . Patients know allergic Shenfu Injection component patient serious adverse effect ; 14 . Patients potential contraindication CMR ; 15 . Participation clinical trial recent 3 month ; 16 . Patients complete trial comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Shenfu Injection</keyword>
	<keyword>Reperfusion Injury</keyword>
	<keyword>Myocardial Protection</keyword>
	<keyword>Percutaneous Coronary Intervention</keyword>
</DOC>